

# 6TH WORLD FORUM ON BREAST AND CERVICAL CANCER



<sup>1</sup>**Prof. Attila L. Major, MD, PhD,** <sup>2</sup>**Prof. Kudrat Jumaniyazov,** <sup>3</sup>**Dr. Mukhabbat Akhmedova**

<sup>1</sup>Femina Gynecology Center, Geneva, Switzerland

<sup>2</sup>Urgench Branch of Tashkent Medical Academy, Uzbekistan

<sup>3</sup>Tashkent Medical Academy, Uzbekistan

## **Evolving Strategies in Cervical Cancer Prevention: The Role of biomarkers and a novel adsorbent and antioxidative vaginal gel**

Current cervical cancer screening methods, while effective, result in a substantial number of unnecessary conizations -nearly 50%- which may be associated with significant long-term complications, including preterm delivery and infertility. This highlights the urgent need for improved risk stratification while maintaining high diagnostic accuracy.

This presentation will detail a modern, biomarker-driven strategy for prevention. The dual-stain test for p16/Ki-67 (CINtec® PLUS) is a pivotal triage tool for HPV-positive women, objectively identifying transforming infections with high oncogenic potential. Its integration into international guidelines (ASCCP, WHO) significantly improves colposcopy referral accuracy, reducing unnecessary procedures.

For women under surveillance ("wait and watch"), we explore a non-surgical therapeutic intervention. Data from prospective, controlled trials on an adsorbent and antioxidative vaginal gel, a medical device class IIa, will be presented. A 3-month treatment course demonstrates significant promotion of regression of cytological abnormalities (74% in the treatment group TG and 18% compared with the control group CG) and significant clearance of high-risk HPV (51% in TG, 9% in CG) and p16/Ki-67 positivity change (83% TG, 18% CG) compared to watchful waiting. The gel also shows a protective effect against new HPV infections.

In conclusion, the integration of advanced biomarkers like p16/Ki-67 for precise risk stratification, combined with effective non-surgical therapeutic options like this vaginal gel application, represents a modern, patient-centric approach to cervical cancer prevention. This strategy aims to minimize overtreatment and its associated risks while effectively managing precancerous lesions, aligning with the latest clinical guidelines and the goals of preventive medicine.

### **Keywords**

Cervical Cancer Prevention, HPV, p16/Ki-67, adsorbent and antioxidative vaginal gel, Conization, Overtreatment.

# 6TH WORLD FORUM ON BREAST AND CERVICAL CANCER

## References

1. Egemen D, Cheung LC, Chen X, et al. Risk Estimates Supporting the 2019 ASCCP Risk-Based Management Consensus Guidelines. *J Low Genit Tract Dis.* 2020;24(2):132-143. doi:10.1097/LGT.0000000000000529
2. Major AL, Dvořák, V, Schwarzová J, et al. Efficacy and safety of an adsorbent and anti-oxidative vaginal gel on CIN1 and 2, on high-risk HPV, and on p16/Ki-67: a randomized controlled trial. *Arch Gynecol Obstet.* (2020). doi.org/10.51219/URForum.2025.Niels-Henrik-Hollander10.1007/s00404-020-05816-8
3. Major AL, Skřivánek A, Grandjean EM, et al. An Adsorptive and Antioxidant Vaginal Gel Clears High-Risk HPV- and p16/Ki-67-Associated Abnormal Cytological Cervical Findings: A post-hoc Subgroup Analysis of a Prospective Randomized Controlled Trial on CIN2 and p16 Positive CIN1. *Front Med (Lausanne).* 2021;8:645559. Published 2021 May 25. doi:10.3389/fmed.2021.645559
4. Major AL, Mayboroda I, Riger A. Successful Preventive Treatment of Oncogenic Transforming HPV Infections in Low-Grade Cytology (ASC-US/LSIL) Patients with an Adsorptive and Antioxidant Vaginal Gel. *J Clin Med.* (2023) doi.org/10.51219/URForum.2025.Niels-Henrik-Hollander10.3390/jcm12124142.

## Biography

Prof. Attila Louis Major, MD, PhD, is Head of the Femina Gynecology Center in Geneva, Privatdocent at the University of Fribourg and Professor of Urgench Branch of Tashkent Medical Academy. He is a Swiss and European board-certified specialist in gynecology and obstetrics, with previous senior appointments at the University Hospitals of Geneva and Zurich. His main research interests include cervical cancer prevention, biomarker-driven risk stratification, non-surgical therapeutic interventions, and advanced laparoscopic techniques. Author of numerous peer-reviewed publications and Associate Editor of *Frontiers in Medicine*, he has been recognized with multiple international awards in gynecologic oncology and minimally invasive surgery